Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 7Neuromyelitis Optica 2Recurrence 1Optic Neuritis 1Myelitis, Transverse 1Hemoglobinuria, Paroxysmal 1Demyelinating Diseases 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

fludarabine phosphate 7Whole-Body Irradiation 6Melphalan 6Peripheral Blood Stem Cell Transplantation 5Stem Cell Transplantation 4Mycophenolic Acid 4Antibodies 4thymoglobulin 3Tacrolimus 3Methotrexate 3Cyclophosphamide 3Busulfan 3Antilymphocyte Serum 3Alemtuzumab 3Cyclosporine 2treosulfan 1sargramostim 1ravulizumab 1merphos 1fludarabine 1bryostatin 1 1X-Rays 1Transplantation, Homologous 1Thiotepa 1Sirolimus 1Rituximab 1Observation 1Muromonab-CD3 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoglobinuria, Paroxysmal × ravulizumab × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔